Analysts See $1.79 EPS for Mallinckrodt Public Limited Company (MNK)

October 13, 2018 - By Hazel Jackson

Investors sentiment decreased to 0.77 in 2018 Q2. Its down 0.13, from 0.9 in 2018Q1. It fall, as 44 investors sold Mallinckrodt Public Limited Company shares while 90 reduced holdings. 48 funds opened positions while 55 raised stakes. 95.84 million shares or 0.62% less from 96.44 million shares in 2018Q1 were reported.
Profund Advsrs Lc has invested 0.01% in Mallinckrodt Public Limited Company (NYSE:MNK). Public Sector Pension Investment Board holds 76,000 shares. Jefferies Gp Ltd Limited Liability Company holds 0.01% in Mallinckrodt Public Limited Company (NYSE:MNK) or 52,961 shares. Mackenzie Financial Corp holds 0.01% or 155,450 shares. 43,818 were reported by Royal Bancorp Of Canada. Private Advisor Grp Ltd holds 0.02% or 50,808 shares in its portfolio. Omers Administration has 16,100 shares for 0% of their portfolio. Trust Of Vermont has 50 shares. First Lp holds 0.06% or 1.55 million shares. Raymond James And Assocs invested in 15,253 shares or 0% of the stock. The Switzerland-based Swiss Commercial Bank has invested 0% in Mallinckrodt Public Limited Company (NYSE:MNK). Brandywine Investment Mngmt Ltd reported 619,354 shares or 0.07% of all its holdings. Captrust Financial Advsrs stated it has 0% in Mallinckrodt Public Limited Company (NYSE:MNK). Bokf Na holds 0.01% or 13,876 shares in its portfolio. Fmr Limited Liability Corp owns 2.31M shares.

Since May 9, 2018, it had 1 buy, and 1 insider sale for $4.14 million activity. Flynn James E sold $4.19 million worth of stock or 312,928 shares.

Analysts expect Mallinckrodt Public Limited Company (NYSE:MNK) to report $1.79 EPS on November, 6.They anticipate $0.18 EPS change or 9.14 % from last quarter’s $1.97 EPS. MNK’s profit would be $148.95 million giving it 3.79 P/E if the $1.79 EPS is correct. After having $1.78 EPS previously, Mallinckrodt Public Limited Company’s analysts see 0.56 % EPS growth. The stock increased 3.78% or $0.99 during the last trading session, reaching $27.16. About 1.58 million shares traded. Mallinckrodt Public Limited Company (NYSE:MNK) has declined 12.43% since October 14, 2017 and is downtrending. It has underperformed by 28.05% the S&P500.

Mallinckrodt Public Limited Company (NYSE:MNK) Ratings Coverage

Among 12 analysts covering Mallinckrodt (NYSE:MNK), 1 have Buy rating, 3 Sell and 8 Hold. Therefore 8% are positive. Mallinckrodt had 19 analyst reports since April 20, 2018 according to SRatingsIntel. The stock of Mallinckrodt Public Limited Company (NYSE:MNK) earned “Underweight” rating by Barclays Capital on Wednesday, August 8. The company was maintained on Monday, April 23 by Leerink Swann. Morgan Stanley maintained it with “Equal-Weight” rating and $35 target in Friday, August 17 report. The rating was downgraded by Raymond James to “Market Perform” on Wednesday, August 8. The rating was maintained by Stifel Nicolaus on Monday, June 18 with “Hold”. The stock of Mallinckrodt Public Limited Company (NYSE:MNK) earned “Market Perform” rating by Wells Fargo on Monday, July 9. The rating was maintained by Morgan Stanley with “Equal-Weight” on Wednesday, May 9. The firm has “Hold” rating given on Friday, May 18 by Mizuho. The firm earned “Neutral” rating on Thursday, June 28 by FBR Capital. The rating was downgraded by Goldman Sachs to “Sell” on Tuesday, September 11.

Mallinckrodt public limited company develops, makes, markets, and distributes branded and generic specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. The company has market cap of $2.26 billion. The company's Specialty Brands segment markets branded pharmaceutical products for autoimmune and rare diseases, including the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and hemostasis products, and central nervous system drugs. It has a 1.46 P/E ratio. This segment offers Acthar, an injectable drug for various indications, such as neurology, rheumatology, nephrology, and pulmonology; Ofirmev, an intravenous formulation of acetaminophen for pain management; Inomax for inhalation; Therakos, an immunotherapy treatment platform; and Exalgo, a form of hydromorphone.

More recent Mallinckrodt Public Limited Company (NYSE:MNK) news were published by: Seekingalpha.com which released: “Mallinckrodt down 17% on FDA nod for Praxair’s generic Inomax” on October 04, 2018. Also Benzinga.com published the news titled: “Jefferies: Reaction In Mallinckrodt Shares To Praxair Competition Overblown” on October 05, 2018. Seekingalpha.com‘s news article titled: “FDA announces joint advisory committee review of Mallinckrodt’s Roxicodone” with publication date: October 08, 2018 was also an interesting one.

Mallinckrodt Public Limited Company (NYSE:MNK) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>